Cellular Biomedicine Group Completes Patient Treatment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee

Cellular Biomedicine Group Completes Patient Treatment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis  PALO ALTO, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company") today announced that it has treated the final patient in its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin^TM for Knee Osteoarthritis (KOA).  Dr. William (Wei) Cao, Chief Executive Officer of the Company, commented, "The patient enrollment and treatment were carried out smoothly and completed earlier than anticipated. There have been no Severe Adverse Events (SAE) observed to date. We are very pleased with the progress of ReJoin^TMtherapy Phase IIb trial. The excellent readout from the six-month follow-up of the Phase I/IIa trial makes us optimistic about theresults of the Phase IIb trial, which will be announced in the first quarter of 2015." A Phase I/IIa twelve-month follow-up MRI readout has been completed and we expect the official report to be available by early fourth quarter of 2014.  Full data analysis will be carried out by FuDan Medical University Department of Biostatistics, one of the most authoritative biostatistics institutions in China.  The Phase I/IIa clinical trial for this therapy was completed in the fourth quarter of 2013, with the six-month follow-up data analysis concluding that ReJoin^TM cell therapy for KOA patients is safe and revealing an increase in cartilage volume as early as three months after the therapy. (click here to view detailed six-month data).  About the Clinical Trial  The Phase IIb clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under the number NCT02162693 (click here to view), is led by Shanghai Renji Hospital, one of the largest teaching hospitals in China. The multi-center study enrolled 53 patients to participate in a randomized, single-blind trial.  The primary endpoints for this trial are knee-related pain, stiffness and function as measured using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index questionnaire. The secondary endpoints are cartilage repair at six months by assessment of changes of the knee joint cartilage's volume measured with quantitative magnetic resonance imaging (MRI), in addition to NRS-11, SF-36 and KSCRS scores, and the recording of any moderate to serious adverse events.  About Cellular Biomedicine Group  Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors fromChinaandthe United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com  Forward-Looking Statements  Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.  CONTACT: Sarah Kelly          Director of Corporate Communications, CBMG          +1 650 566-5064          sarah.kelly@cellbiomedgroup.com                   Vivian Chen          Managing Director Investor Relations, Grayling          +1 646 284-9427          vivian.chen@grayling.com  Cellular Biomedicine Group Inc. Logo  
Press spacebar to pause and continue. Press esc to stop.